All friends and partners of Minkang:

As 2022 comes to an end, on behalf of the company, I would like to express my great thanks to you for your hard work and support!

Looking back on the past 2022, it was a difficult year for Minkang. In 2022, we have witnessed the efforts of the R&D team, the struggle of the production team, the breakthrough of the marketing team and the improvement of the service team. Because of this, Minkang has the determination and confidence to stride forward. In this process, each of us is a participant, navigator and master.

We have entered into 2023, which is bound to be a year for Minkang to make a leap forward, and also an important milestone for us to start a new phase of Minkang. In the new year, our work will be "on the rise in an all-round way", and our key work will be "strong breakthrough". The project of artificial pancreas (i.e. continuous dynamic glucose meter, adhesive insulin pump) will enter the clinical stage in an all-round way. The wholly-owned Anhui Progression Biotechnology Co., Ltd. is expected to be completed and put into operation as scheduled, and the production capacity will be improved by leaps and bounds. With the release of new products, the market share of Minkang Blood Glucometer will increase by 15% within the year. In the new year, we need to work steadily and step by step to do "addition", seek and build momentum and then use it to do "multiplication".

In the new year, our work benchmark must not be lowered. We should actively promote the transformation of safety production from "full participation" to "full performance", and fully implement the transformation of project research and development from "raising questions" to "showing results", which will be an important presentation of our future core competitiveness of Minkang! 

In 2023, I wish our agent friends "A good start, a good season and a good year"! I wish everyone in Minkang success, good health and family happiness!

Happy New Year to everyone!